# Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure

Study · id `cardio:ct-nct05232292` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05232292](<https://clinicaltrials.gov/study/NCT05232292>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05232292

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05232292. Randomized; no masking; primary purpose prevention. Start 2021-10-06 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05232292, source copy `cardio:ctgov-nct05232292-2022-02-09`, retrieved 2026-10-31)
- Started: 2021-10-06 (actual) (ClinicalTrials.gov record NCT05232292, source copy `cardio:ctgov-nct05232292-2022-02-09`, retrieved 2026-10-31)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT05232292, source copy `cardio:ctgov-nct05232292-2022-02-09`, retrieved 2026-10-31)
- Completion: 2023-05-31 (anticipated) (ClinicalTrials.gov record NCT05232292, source copy `cardio:ctgov-nct05232292-2022-02-09`, retrieved 2026-10-31)
- Countries: Russia (ClinicalTrials.gov record NCT05232292, source copy `cardio:ctgov-nct05232292-2022-02-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05232292-2022-02-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure
- Acronym: IV-ACS&CHF
- Condition: Acute Coronary Syndrome
- Condition: Chronic Heart Failure
- Intervention (Biological): Ultrix Quadri
- Lead sponsor: Samara Regional Cardiology Dispensary
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)

## Provenance

Content hash: 661e7b65359628b2506375749995119a6ce4a875f7ea63cc3b634ab623722c8b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
